Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 4:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: CPA Clear all
Completed Phase 2 Interventional Results available

BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

NCT01830127
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin, BI 207127 high dose, Faldaprevir, BI 207127 low dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
6
States / cities
La Mesa, California • San Diego, California • DeLand, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Sep 6, 2026, 4:24 AM EDT
Terminated Phase 1 Interventional

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

NCT02387125
View directory record Official record
Conditions
Sarcoma, Melanoma, Non-small Cell Lung Cancer, Ovarian Cancer
Interventions
CMB305, G100, Metronomic CPA
Biological · Drug
Lead sponsor
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Santa Monica, California • New Haven, Connecticut • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Sep 6, 2026, 4:24 AM EDT
Completed Not applicable Interventional Results available

Compare Preperitoneal Analgesia to Epidural Analgesia for Pain Control After Colon and Rectal Surgery

NCT01552226
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer, Colonic Diverticulosis
Interventions
Continuous Preperitoneal Analgesia, Continuous Epidural Analgesia
Device
Lead sponsor
Trinity Health Michigan
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 6, 2026, 4:24 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2

NCT03152318
View directory record Official record
Conditions
Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Oligodendroglioma, Anaplastic Oligodendroglioma of Brain (Diagnosis), Mixed Oligo-Astrocytoma, Ependymoma, Ganglioglioma, Pylocytic/Pylomyxoid Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme
Interventions
rQNestin, Cyclophosphamide, Stereotactic biopsy
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
5
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 6, 2026, 4:24 AM EDT
Terminated Phase 2 Interventional

Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer

NCT05243524
View directory record Official record
Conditions
Platinum-resistant Epithelial Ovarian Cancer
Interventions
Maveropepimut-S, Cyclophosphamide 50mg
Other · Drug
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Palo Alto, California • Ocala, Florida • Mineola, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 6, 2026, 4:24 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Improving Anticipatory and Compensatory Postural Responses to Avoid Falls After TBI

NCT05268484
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Perturbation-based Training with visual cues using Neurocom
Device
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 6, 2026, 4:24 AM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

The Effects of Aging and Estrogen on the Pituitary

NCT00386022
View directory record Official record
Conditions
Healthy
Interventions
GnRH, NAL-GLU GnRH antagonist, Estrogen patch
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 80 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 6, 2026, 4:24 AM EDT
Completed Phase 1 Interventional

Trial of Vasopressin and Epinephrine to Epinephrine Only for In-Hospital Pediatric Cardiopulmonary Resuscitation

NCT00628550
View directory record Official record
Conditions
Cardiopulmonary Arrest, Cardiac Arrest
Interventions
Vasopressin, Epinephrine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Up to 18 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Sep 6, 2026, 4:24 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome

NCT04327934
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Hypertension
Interventions
GnRH antagonist, GnRH antagonist + MethylTESTOSTERone 5 MG
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Sep 6, 2026, 4:24 AM EDT
Completed Phase 1Phase 2 Interventional

Combined Modality Treatment for Patients With Stage IV Melanoma

NCT00313235
View directory record Official record
Conditions
Malignant Melanoma Stage IV
Interventions
DC Vaccine and Cyclophosphamide
Biological
Lead sponsor
Baylor Research Institute
Other
Eligibility
21 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2013 · Synced Sep 6, 2026, 4:24 AM EDT
Terminated No phase listed Observational

Effectiveness of Manual Physical Therapy to Improve Endocrine Levels in Women

NCT02027168
View directory record Official record
Conditions
FSH Hypersecretion, Endocrine System Diseases, Infertility
Interventions
CPA
Other
Lead sponsor
Clear Passage Therapies, Inc
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Sep 6, 2026, 4:24 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Metabolic Effects of Steroids in Obese Men

NCT00983554
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Anastrazole, Testosterone, Dutasteride, GnRH antagonist
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
24 Years to 51 Years · Male only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 15, 2011 · Synced Sep 6, 2026, 4:24 AM EDT
Terminated Phase 3 Interventional Results available

Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer

NCT02049151
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Tecemotide, Placebo, Cyclophosphamide (CPA), Saline (sodium chloride)
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Sep 6, 2026, 4:24 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Letrozole Treatment in Normal and GnRH Deficient Women

NCT00351416
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Letrozole, NAL-GLU GnRH antagonist
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Sep 6, 2026, 4:24 AM EDT
Withdrawn Phase 4 Interventional

Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy

NCT00507780
View directory record Official record
Conditions
Ovarian Function, Preservation of Ovarian Function
Interventions
GnRH antagonist
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
10 Years to 21 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 6, 2026, 4:24 AM EDT
Completed Phase 4 Interventional Results available

MENOPUR® Versus FOLLISTIM®

NCT00802360
View directory record Official record
Conditions
Infertility
Interventions
Menotropin, Progestrone vaginal insert, follitropin beta, Progesterone in oil, Ganirelix
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 42 Years · Female only
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Pasadena, California • San Diego, California • Littleton, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2011 · Synced Sep 6, 2026, 4:24 AM EDT
Recruiting Phase 1 Interventional

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

NCT06613100
View directory record Official record
Conditions
Prostate Cancer
Interventions
Xaluritamig, GnRH Antagonist
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
7
States / cities
San Francisco, California • St Louis, Missouri • Columbus, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 6, 2026, 4:24 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate

NCT01327495
View directory record Official record
Conditions
Healthy
Interventions
placebo acyline, placebo gel, Testosterone 1% gel 1.25 g, Testosterone 1% gel 2.5 g, Testosterone 1% gel 5.0 g, testosterone 1% gel 10 g, testosterone 1% gel 15 g, Acyline
Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 6, 2026, 4:24 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Bioenergetic Effects of Aging and Menopause (BEAM)

NCT04043520
View directory record Official record
Conditions
Menopause, Obesity, Abdominal, Aging, Weight Gain
Interventions
GnRH antagonist, Estrogen Product, Placebo estradiol, Placebo GnRH antagonist
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced Sep 6, 2026, 4:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Emergency Medicine Pharmacist Impact on Blood Culture Review Following Emergency Department Discharge

NCT07486362
View directory record Official record
Conditions
Bacteremia
Interventions
No Intervention
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 6, 2026, 4:24 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Efficacy of Manual Therapy to Improve Quality of Life and Decrease Pain in Subjects With Endometriosis

NCT03118154
View directory record Official record
Conditions
Endometriosis, Pelvic Pain, Dysmenorrhea
Interventions
Manual Physical Therapy
Other
Lead sponsor
Clear Passage Therapies, Inc
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Sep 6, 2026, 4:24 AM EDT
Completed Not applicable Interventional

Mobilization Versus Manipulation for the Treatment of Cervicogenic Headaches

NCT03919630
View directory record Official record
Conditions
Cervicogenic Headache
Interventions
Thrust Mobilization, Non-Thrust Mobilizations
Other
Lead sponsor
Franklin Pierce University
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Havertown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Sep 6, 2026, 4:24 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study)

NCT05057546
View directory record Official record
Conditions
Menopause, Estrogen Deficiency, Women, Aging
Interventions
GnRH antagonist
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Sep 6, 2026, 4:24 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Cardiometabolic Consequences of the Loss of Ovarian Function

NCT06264882
View directory record Official record
Conditions
Menopause, Estrogen Deficiency, Aging, Adiposity
Interventions
Degarelix, Transdermal Estradiol Patch, Transdermal Placebo Patch
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Sep 6, 2026, 4:24 AM EDT